Lead Product(s) : PBI-200,Ritonavir,Cobicistat
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of PBI-200 With Ritonavir or Cobicistat in Healthy Volunteers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 20, 2023
Lead Product(s) : PBI-200,Ritonavir,Cobicistat
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PBI-200,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Formulation Bridging and Food Effect Study of PBI-200 in Healthy Volunteers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 19, 2023
Lead Product(s) : PBI-200,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PBI-200,Inapplicable
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Caris Life Sciences
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Molecular Intelligence Trials (MI Trials) collaboration will enhance identification of patients with NTRK fusion-positive solid tumors, including primary and metastatic CNS tumors potentially eligible for enrollment in the ongoing PBI-200-101 Phase 1/2 c...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 03, 2022
Lead Product(s) : PBI-200,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Caris Life Sciences
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : PBI-200,Inapplicable
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pyramid Biosciences Receives Orphan Drug Designation for PBI-200 From FDA
Details : PBI-200 is an oral, highly potent, and selective inhibitor of TRK kinase that is currently in clinical development for the treatment of patients with cancers that harbor abnormalities involving the tropomyosin receptor kinases.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 07, 2022
Lead Product(s) : PBI-200,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PBI-200,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Assess the Effect of Food on the Absorption and Bioavailability of PBI-200
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 16, 2021
Lead Product(s) : PBI-200,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 26, 2021